Smith & Nephew (LON:SN) Share Price Passes Below Two Hundred Day Moving Average – What’s Next?

Smith & Nephew plc (LON:SN) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,301.71 and traded as low as GBX 1,276.50. Smith & Nephew shares last traded at GBX 1,284.50, with a volume of 2,177,995 shares.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Panmure Gordon reaffirmed a “hold” rating and set a GBX 1,200 price objective on shares of Smith & Nephew in a report on Tuesday, December 9th. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and lowered their target price for the company from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Finally, Berenberg Bank reaffirmed a “hold” rating and set a GBX 1,300 price target on shares of Smith & Nephew in a research note on Friday, January 23rd. Two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of GBX 1,381.33.

Smith & Nephew Stock Performance

The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90. The stock has a market cap of £14.08 billion, a price-to-earnings ratio of 46.25, a PEG ratio of 0.46 and a beta of 0.68. The stock’s fifty day moving average is GBX 1,271.47 and its 200-day moving average is GBX 1,301.71.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.